Related Experiment Video

Updated: Jul 14, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update

Eszter M Horvath1, Csaba Szabó

  • 1Department of Surgery, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103-2714, USA.

Drug News & Perspectives
|May 24, 2007
PubMed

Insights

Poly(ADP-ribose) polymerase-1 (PARP-1) plays a dual role in cell survival and death. PARP inhibition offers therapeutic potential for cancer and cardiovascular diseases, with new inhibitors advancing to clinical trials.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genetics

Background:

  • Poly(ADP-ribose) polymerase-1 (PARP-1) is a crucial nuclear protein involved in DNA repair.
  • PARP-1 acts as a DNA nick sensor, initiating cellular responses to DNA damage.
  • The PARP enzyme family includes PARP-1 and four other related enzymes.

Purpose of the Study:

  • To review recent advancements in Poly(ADP-ribose) polymerase-1 (PARP-1) research.
  • To explore the dual role of PARP-1 in genomic integrity and cell death.
  • To highlight the therapeutic potential of PARP inhibitors in various diseases.

Main Methods:

  • Review of current scientific literature on PARP-1.
  • Analysis of novel PARP inhibitors and genetically engineered animal models.
  • Examination of clinical trial data for PARP inhibitors.

Main Results:

  • PARP-1 inhibition can induce tumor cell death, alone or with other agents.
  • Overactivation of PARP-1 contributes to cell dysfunction and death in pathological conditions.
  • PARP inhibition demonstrates cytoprotective effects in diseases like stroke, heart attack, and diabetes.

Conclusions:

  • PARP-1 is a significant target for therapeutic intervention.
  • PARP inhibitors show promise in treating cancer and cardiovascular diseases.
  • Ongoing research and clinical trials are expanding the applications of PARP inhibitors.

More Related Videos

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: